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METHODS AND PRODUCTS FOR 
REAWAKENING RETROCYCLINS 
FIELD OF THE INVENTION 
The present invention relates to products and methods for 
the restoring the endogenous expression of theta-defensins, 
such as retrocyclin polypeptides, in a host cell. The present 
invention also relates to products and methods for inhibiting 
HIV-1 virus entry into a host cell via, for example, adminis-
tering to a subject an amount of a read-through mediating 
agent sufficient to induce exogenous expression of an amount 
of retrocyclin polypeptides in the host cell. 
BACKGROUND OF THE INVENTION 
Nearly 33 million people are infected with HIV worldwide 
[1,2], and despite extensive efforts, there are no effective 
vaccines or other countermeasures to protect against HIV 
transmission [3]. Previous attempts to find effective anti-HIV 
agents have determined that certain synthetic 8-defensins 
called "retrocyclins" or "retrocyclin polypeptides" are potent 
inhibitors of HIV-1 infection [ 4-8]. Retrocyclins belong to a 
large family of antimicrobial peptides known as defensins, all 
2 
TZM-bl cells were treated with extracts or peptide as indi-
cated in the figure and infected with HIV-1 BaL (6.5 ng/ml 
p24) for 24 hr. Infection was measured as percent luciferase 
activity compared to cells treated with control cell extract 
5 (Average RLU of control HL60 extract=l 78,200). (B, C) 
PM! cells and PBMCs were treated with extracts or peptide 
as indicated and infected with HIV-1 BaL (2 ng/ml p24) and 
cultured for 5-9 days. Bars represent percent BaL HIV-1 
levels in the supematants collected on days 5 (B) and 9 (C). 
10 The amount of p24 in PM! cells treated with control 
extract=76.85 ng/ml and in PBMCs treated with control 
extracts=55.99 ng/ml. (D) TZM-bl cells were treated with 
immunopurified (IP) extracts or peptides as indicated and 
infected with BaL HIV-1 (p24=2 ng/ml) for 24 hr. Infection 
15 was quantified as percent luciferase activity compared to cells 
treated with control HL60 cell IP extracts (Average 
RLU=764,460). Error bars represent SEM. n=3-4, #P<0.004, 
*P<0.002, **P<0.0005. (E) CellularviabilityofTZM-bl cells 
treated with HL60 acid extracts as indicated was determined 
20 by measuring the reduction of MTT after 24 h (n=3). Bars 
represent percent viability as compared to vehicle control and 
error bars represent SEM. (F) Cell death was monitored in 
PBMCs treated with the acid extracts by a trypan blue exclu-
sion assay on day 9 (n=l). 
of which are cationic, tri-disulfide bonded peptides that have 25 
important roles in innate host defense. Based on the position 
FIG. 3: Immunofluorescence staining of stably transfected 
HL60 cells reveals retrocyclin peptides. (A) Retrocyclin pep-
tides RC-100, RC-101 and RC-101_2K peptides (in dupli-
cates) and (B) RC-100, RC-lOOb, RC-101, protegrin-1 (PG-
1 ), rhesus theta defensin-1 (RTD-1 ), and human neutrophil 
of the cysteines and the disulfide bonding pattern, defensins 
are grouped into 3 subfamilies: a-defensins, ~-defensins and 
8-defensins [9, 10]. 
30 peptides 1-3 (HNP 1-3) were dotted (0-8 ng/4 µl dot) on a 
PVDF membrane and subjected to immuno-dotblot analysis. 
(C) Vector control, R1R3 and A1A3 (100,000 cells each) 
were fixed onto glass slides and incubated with rabbit anti-
RC-101 antibody followed by biotinylated goat anti-rabbit 
8-Defensins such as retrocyclinhave a cyclic peptide back-
bone, derived from the head-to-tail-ligation of two nonapep-
tides that each contributes nine amino acids to form the 18 
residue mature polypeptide [11]. 8-Defensins are the only 
known cyclic peptides in mammals and were originally iso-
lated from rhesus macaque leukocytes and bone marrow [11-
13]. While 8-defensin peptides, e.g., retrocyclin polypep-
tides, are produced in old world monkeys and orangutans, in 
humans they exist only as expressed pseudogenes [14]. Criti-
cally, a premature termination codon in the signal peptide 
portion of human retrocyclin mRNA prevents its translation. 40 
The retrocyclin gene is otherwise remarkably intact, showing 
89.4% identity with rhesus 8-defensins. Its genetic informa-
tion was utilized to recreate retrocyclins synthetically and 
confirm their activity against both X4 and R5 strains ofHIV-1 
[ 4-7]. To date, however, there has not yet been developed an 
agent or process for restoring the mammalian body's ability 
to endogenously produce retrocyclin peptides. 
BRIEF DESCRIPTION OF THE DRAWINGS 
35 IgG secondary antibody and then stained using FITC-avidin. 
Slides were visualized using Zeiss Axiovert 200M micro-
scope system at 40x magnification. The three rows show 
FITC staining, DIC and the merged image respectively. Scale 
bar represents 20 µm. 
FIG. 4: Stably transfected promyelocytic cells produce 
retrocyclin. (A) Shows the RP-HPLC trace of A1A3 cell 
extract (from 108 cells) and 50 µg of synthetic RC-101. (B) 
Western blot of A1A3 HPLC fractions (23-28 min) using 
rabbit anti-RC-101 antibody. The arrows indicate the multi-
45 meric forms of retrocyclin observed in A1A3 fractions. (C) 
TZM-bl cells were infected with HIV-1 (p24=2 ng/ml) in the 
presence or absence ofpooledA1A3 fractions (final dilution 
1:6 in DlO) or 2 µg/ml of RC-101 for 24 hr. Infection was 
quantified by luciferase measurement (Average RLU of 
50 Vehicle control with virus=85,450). Error bar represents 
SEM and n=3-6, *P<0.0015 **P<0.0001. MALDI-TOF MS 
spectra of Lys-C digested (D) synthetic RC-101_2K, (E) 
synthetic RC-101 and (F)A1A3 HPLC fraction 26 reveal that 
FIG.1: Design ofretrocyclin constructs. (A) Shows a sche-
matic of the 4 constructs (Rl, R3, Al andA3) used for stable 
transfections along with native retrocyclin cDNA, which 
encodes the retrocyclin nonapeptide (SEQ ID NO. 10). All 
constructs have two termination codons at the end to ensure 55 
read-fidelity. Constructs Al and A3 contain additional down-
stream residues while constructs Rl and R3 lack them. The 
two arrows indicate the position at which the two site-directed 
mutagenesis (0 l 7Q and R70K) were performed. (B) Shows 
the three possible mature retrocyclin peptides that could be 
formed from the constructs, homodimers ofRl or Al encod-
ing RC-100 (wild type retrocyclin), heterodimers of Al and 
A3 or Rl and R3 encoding RC-101 (single lysine congener) 
and homodimers ofR3 or A3 encoding RC-101_2K (double 
lysine congener). 
A1A3 cells produce RC-101. 
FIG. 5: Aminoglycosides mediate read-through of the pre-
mature termination codon within the retrocyclin gene and 
promote anti-HIV-1 activity. (A) Shows a schematic repre-
sentation of the luciferase fusion constructs unrescued 
RC-101 and rescued RC-101 along with native retrocyclin 
60 cDNA which encodes the retrocyclin nonapeptide (SEQ ID 
NO. 10). (B) HOS-CD4-CCR5 cells cultured in antibiotic 
free medium (DlO-) were transfected with unrescued 
RC-101 (negative control) or rescued RC-101 (positive con-
trol) plasmids along with phRL-CMV vector (transfection 
65 control). The next day transfected cells were treated with PBS 
for control cells or aminoglycosides at the indicated concen-
trations and allowed to grow for 24 hr. Read-through was 
FIG. 2: Extracts from HL60 cells stably transfected with 
retrocyclin constructs are active against HIV-1 infection. (A) 
US 8,765,698 B2 
3 
determined by measuring luciferase levels. Data is expressed 
as fold increase in luciferase expression normalized to renilla 
levels. (C) TZM-bl cells grown in DlO- were treated for 30 
min with PBS, RC-101 (2.5 µg/ml), RC-100 (2.5 µg/ml) or 
aminoglycosides as shown in the figure and infected with 5 
HIV-1 BaL (2 ng/ml p24) for 24 hr followed by luciferase 
measurement. Error bars represent SEM. n=3-6, #P<0.007 
*P<0.0005 **P<0.0001. (D) TZM-bl cells cultured on cover 
slips were treated with PBS (Con) or 10 µg/ml tobramycin 
(Tob) and then immunostained with rabbit pre-immune or 10 
anti-retrocyclin serum using a biotinylated secondary anti-
body FITC-avidin system. (E) Cellular cytotoxicity was 
assessed by performing an MTT assay on TZM-bl cells 
treated with indicated amount of peptide or aminoglycosides 
(n=3). Bars represent percent metabolic inhibition as com- 15 
pared to control (vehicle+virus). (F) TZM-bl cells, treated 
with either PBS, tobramycin (10 µg/ml) or RC-100 (2.5 
µg/ml), were incubated with preimmune serum or anti-retro-
cyclin serum as indicated and infected with HIV-1 (p24 of 5 
ng/ml). Data is represented as percent infection. Error bars 20 
represent SEM. n=3, +P<0.018 Statistical significance was 
determined by two-tailed Student t-test. 
FIG. 6: Expression ofretrocyclins in cervicovaginal tissue 
model using aminoglycosides. (A) Cervicovaginal tissues 
were treated with PBS (Con) or 10 µl tobramycin (Tob) and 25 
incubated with rabbit pre-immune serum or anti-retrocyclin 
antibody. The slides were then incubated with biotinylated 
goat anti-rabbit IgG secondary antibody and then stained 
using FITC-avidin. (B) Cytotoxicitywas determined by mea-
suring Lactate dehydrogenase (LDH) activity inmedia under- 30 
lying the tissues treated with PBS or tobramycin as indicated. 
Bars represent absorbance measured as 490 nm and error bars 
represent SEM; n=6. (C) HPLC trace of extracts of tissues 
treated with 10 µg/ml tobramycin (Tissue+ Tob) and 20 µg of 
synthetic RC-100. (D) RC-100 synthetic peptide (indicated 35 
amounts), HPLC fractions 27-29 of control, tobramycin-
treated and RC-100 were dotted on a PVDF membrane and 
analyzed by immuno-dotblot. 
FIG. 7: Verification of stable transfection of retrocyclin 
constructs. Analysis of the genomic DNA and RNA of trans- 40 
fected HL60 cells confirms the stable transfection and tran-
4 
ducing the modified sequence into a host cell via a delivery 
and expression vector (or "delivery vector"). In another 
embodiment, the ability to endogenously produce retrocylin 
peptides is done via administering an amount of a read-
through mediating agent that is effective to read-through an 
existing premature codon to allow for expression of the ret-
rocyclin polypeptide. In this way, utilizing aspects of the 
present invention, mammalian host cells may synthesize bio-
logically active retrocyclin polypeptides forthe first time. The 
produced biologically active retrocyclin polypeptides may be 
utilized as an effective and natural way of combating sexually 
transmitted infections (STI's), e.g., HIV-1 infection. For 
example, in an aspect of the present invention, there is pro-
vided a method of inhibiting sexually transmitted virus entry 
into a human cell of a mammalian subject comprising admin-
istering an amount of a read-through mediating agent, e.g., 
aminoglycosides effective to produce retrocyclin polypep-
tides in the mamallian subject. 
In accordance with one aspect of the present invention, 
there is provided a process for inducing expression of a ret-
rocyclin polypeptide in a host cell. The process comprises 
introducing a delivery vector into the host cell, wherein the 
delivery vector comprises a polynucleotide having a nucle-
otide sequence that encodes for a retrocyclin polypeptide 
comprising a sequence according to SEQ. ID. NO: 8 or SEQ. 
ID. NO: 9, or variants thereof. The introduction of the deliv-
ery vector into the host cell results in the expression of the 
retrocyclin polypeptide in the host cell. 
In accordance with another aspect of the present invention, 
there is provided a delivery and expression vector for trans-
fecting a cell with an expression construct that encodes for a 
retrocyclin polypeptide. The expression construct comprises 
a polynucleotide sequence encoding SEQ. ID. NO: 8 or SEQ. 
ID. NO: 9, or variants thereof. The expression construct com-
prises SEQ. ID. NO: 1, SEQ. ID NO: 2, SEQ. ID. NO: 3, or 
SEQ. ID NO: 4, or variants thereof. 
In accordance with another aspect of the present invention, 
there is provided a method for reducing virus entry into a host 
cell of a mammalian subject comprising administering to the 
mammalian subject an amount of an expression construct 
encoding a retrocyclin polypeptide. The expression construct 
comprises a polynucleotide sequence encoding SEQ. ID. NO: 
8 or SEQ. ID. NO: 9, or variants thereof. 
The terms "variant or variants" as used herein refer to 
scription of rescued retrocyclin constructs respectively. (A) 
PCR on genomic DNA template from transfected HL60 cells 
shows a 215 bp fragment representing retrocyclin cDNA 
construct and a 890 bp fragment of native retrocyclin gene in 
the genomic DNA of A1A3 clones but not in the Vector 
control (VC) cells. (B, C) Correction of the premature termi-
nation codon of retrocyclin cDNA introduces an additional 
HpyCH4V restriction site the middle of a 87 bp cDNA frag-
ment. RNA isolated from HL60 cells (control, Rl R3 clones 1 
& 2 and A1A3 clones 1 & 2) was used to make cDNA. 
Retrocyclin constructs were amplified by PCR using the 
cDNA as template and digested using HpyCH4V restriction 
enzyme. Electrophoresis of the digested PCR products shows 
the expected 87 bp fragment in control cells (B) and the 
expected absence of 87 bp fragment in R1R3 and A1A3 
clones (C). All the products were also verified by DNA 
sequencing. 
45 nucleotide and polypeptide sequences wherein the nucleotide 
or amino acid sequence exhibits substantial identity with the 
nucleotide or amino acid sequence of the SEQ ID NOs, set 
forth herein, preferably 75% sequence identity and most pref-
erably 90-95% sequence identity to the sequences of the 
DETAILED DESCRIPTION OF THE INVENTION 
The present inventor has surprisingly restored the endog-
enous expression of the evolutionarily lost retrocyclin 
polypeptides in host cells by multiple processes. In one 
embodiment, the ability to endogenously produce retrocyclin 
polypeptides is done by ablating an existing premature ter-
mination codon using site-directed mutagenesis and intro-
50 present invention: provided said variant has a biological 
activity as defined herein. The variant may be arrived at by 
modification of the native nucleotide or amino acid sequence 
by such modifications as insertion, substitution or deletion of 
one or more nucleotides or amino acids or it may be a natu-
55 rally occurring variant. The terms "variant" or "variants" also 
include homologous sequences which hybridize to the 
sequences of the invention under standard or preferably strin-
gent hybridization conditions familiar to those skilled in the 
art. Examples of the in situ hybridization procedure typically 
60 used are described in (Tisdall et al., 1999); (Juengel et al., 
2000). Where such a variant is desired, the nucleotide 
sequence of the native DNA is altered appropriately. This 
alteration can be made through elective synthesis of the DNA 
or by modification of the native DNA by, for example, site-
65 specific or cassette mutagenesis. Preferably, where portions 
of cDNA or genomic DNA require sequence modifications, 
site-specific primer directed mutagenesis is employed, using 
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techniques standard in the art. In addition, "variant" or "vari-
ants" may encompass amino acid sequences comprising one 
amino acid substitution with SEQ. ID. NO: 8 or SEQ. ID. NO: 
9 (as set forth herein) or two consecutive amino acid substi-
tutions with SEQ. ID. NO: 8 or SEQ. ID. NO: 9. 
In one embodiment, the variants of SEQ. ID. NO: 8 or 
SEQ. ID. NO: 9 as set forth herein comprise a polypeptide 
having the following sequence: 
(I) Cys (II) Cys (III) (IV) (V) (VI) Cys 
wherein (I) ~ Arg or Lys 
wherein (II) ~ Ile, Leu, Glu, or Val 
wherein (III) ~ Gly, Ile, Leu, or Val 
wherein (IV) ~ Arg or Lys 
wherein (V) ~ Gly, Ile, Leu, or Val 
wherein (VI) ~ Ile, Leu, Glu, or Val. 
The delivery vector may be a viral or non-vector as is 
known in the art, including but not limited to, single-stranded 
and double-stranded nucleic acid vectors as well as DNA, 
RNA, and DNA/RNA chimeric vectors. Exemplary viral vec-
tors include, but are not limited to, adenovirus, herpesvirus, 
lentivirus, parvovirus (e.g., AAV), baculovirus and Epstein 
Barr Virus vectors. Exemplary non-viral vectors include, but 
are not limited to, plasmid, phage, yeast artificial chromo-
somes (YACs ), Bacterial Artificial Chromosomes (BACs ), 
and naked DNA vectors (e.g., by liposomal delivery), or 
synthetic nucleotide vectors (e.g., vectors that are generated 
by PCR methods or oligonucleotide synthesis, as are known 
in the art). In one particular embodiment, the delivery vector 
is an adeno-associated virus (AAV) vector, e.g., in the form of 
AAV viral particles. In another embodiment, the delivery 
vector is a plasmid. Plasmids are "naked" DNA and do not 
encode genes necessary to encase the genetic material for 
transfer to a new host. The delivery vectors described herein 
may be used in both in vitro and in vivo studies. 
In one embodiment, the host cell is a mammalian host cell, 
e.g., a human host cell. By way of example only, the host cell 
may be an epithelial cell or a myeloid cell, including cells 
from the spleen, bone marrow, thymus, testis, skeletal 
muscle, nasal, nasal mucosa, and cervicovaginal epithelia. 
The expression system comprises multiple polynucle-
otides having a nucleotide sequence that when expressed will 
produce a retrocyclin polypeptide as will be explained below. 
In one embodiment, the encoded retrocyclin polypeptide is a 
homodimer comprising a sequence according to SEQ. ID. 
NO: 8, or variants thereof. In a particular embodiment, the 
retrocyclin polypeptide comprises a homodimer comprising 
two nonapeptides according to SEQ. ID. NO: 8, or variants 
thereof. The nucleotide sequence, which encodes the retro-
cyclin polypeptide according to SEQ. ID. NO: 8, or variants 
thereof, may be represented by SEQ. ID. NO: 1 or SEQ. ID 
N0:2. 
In another embodiment, the encoded retrocyclin polypep-
tide is a homodimer comprising a sequence according to 
SEQ. ID. NO: 9, or variants thereof. In a particular embodi-
ment, the retrocyclin polypeptide comprises a homodimer 
comprising two nonapeptides according to SEQ. ID. NO: 9, 
or variants thereof. The nucleotide sequence, which encodes 
the retrocyclin polypeptide according to SEQ. ID. NO: 9, or 
variants thereof, may be represented by SEQ. ID. NO: 3 or 
SEQ. ID NO: 4. 
In yet another embodiment, the encoded retrocyclin 
polypeptide forms a heterodimer comprising a nonapeptide 
having a sequence according to SEQ. ID. NO: 8, or variants 
thereof, and a nonapeptide having a sequence according to 
SEQ. ID. NO: 9, or variants thereof. The nucleotide sequence, 
6 
which encodes the retrocyclin nonapeptide according to SEQ. 
ID. NO: 8, or variants thereof, may be represented by SEQ. 
ID. NO: 1 or SEQ. ID NO: 2. The nucleotide sequence, which 
encodes the retrocyclin nonapeptide according to SEQ. ID. 
5 NO: 9, or variants thereof, may be represented by SEQ. ID. 
NO: 3 or SEQ. ID NO: 4. 
Turning now to the figures, FIG. lA shows four modified 
retrocyclin-expressing constructs (labeled Rl, R3, Al andA3 
for convenience). Critically, the expression constructs each 
10 correct a premature termination codon found in the naturally 
occurring form of the retrocylin peptide mRNA to enable 
expression of the retrocyclin polypeptide. As shown, the ter-
mination codon at ((i) 17Q) is replaced with a suitable codon, 
such as one encoding for glutamine. Aside from the corrected 
15 premature termination codon ((i) 17Q), all of these con-
structs (Rl, R3, Al, A3) were engineered to contain two 
termination codons at the end of the gene to ensure read-
fidelity. Constructs with an "R" designation terminate after 
the retrocyclin portion of the gene, while constructs with an 
20 "A" designation contain the retrocyclin portion with addi-
tional downstream residues that might be critical for transla-
tion and/or processing [14, 28]. 
Constructs with a" 1" designation (Al, Rl) do not have any 
additional residues mutated, while constructs with a "3" des-
25 ignation (A3, R3) have the additional Arg~Lys mutation 
(R70K) encoding a RC-101 polypeptide. HL60 cells (a 
human promyelocytic cell line) were co-transfected by elec-
troporation with either Rl and R3, or Al andA3, and propa-
gated in the presence ofG418 (300 µg/ml) to create stably 
30 transfected cell lines. In another embodiment, host cells may 
be transfected with any one ofRl, R3, Al, andA3 individu-
ally. Stable transfection was verified by analyzing genomic 
DNA and mRNA primers (FIG. 7). Since two different con-
structs (Rl, R2 and Al, A3) were co-transfected for each 
35 condition, combinatorially it would be possible to generate 
three different retrocyclin peptides as illustrated in FIG. lB. 
For example, if cells were co-transfected with the Rl and R3 
constructs, they could theoretically generate a heterodimer 
(R1R3) or homodimers (RlRl or R3R3). Similarly, if cells 
40 were co-transfected with the Al andA3 constructs, they could 
theoretically generate a heterodimer (A1A3) or homodimers 
(AlAl or A3A3). FIG. lB specifically shows three possible 
mature retrocyclin polypeptides that could be formed from 
the constructs: homodimers of Rl or Al encoding RC-100 
45 (wild type retrocyclin), heterodimers of Al andA3 or Rl and 
R3 encoding RC-101 (single lysine congener) and 
homodimers of R3 or A3 encoding RC-101_2K (double 
lysine congener). 
As shown in FI GS. 2A-2F, the correction of the termination 
50 codon in the retrocyclin constructs restored the translation of 
biologically active retrocyclin polypeptides. The infection of 
TZM-bl cells with HIV-1 BaL was significantly reduced 
when the cells were treated with cellular acid extracts of 
R1R3 cells (P<0.004) andA1A3 cells (P<0.002) (FIG. 2A).A 
55 standard tetrazolium MTT assay revealed that the extracts did 
not affect cellular metabolism at the concentrations used in 
the experiment (FIG. 2E). Addition of A1A3 cell extracts to 
HIV-1 infected PM! cells (FIG. 2B) and PBMCs (FIG. 2C) 
showed a significant (P<0.002 and P<0.004 respectively) 
60 decrease in the viral titer as compared to cells treated with 
control HL60 cell extract. A trypan blue exclusion assay was 
performed in PBMCs to monitor cell viability (FIG. 2F). 
Next, R1R3 and A1A3 cell extracts were affinity purified 
using anti-RC- I 01 antibody and confirmed the antiviral activ-
65 ity in a luciferase-based assay system (FIG. 2D). Interest-
ingly, A1A3 cell extracts were found to be consistently more 
active than equivalent amounts of R1R3 cell extract, which 
US 8,765,698 B2 
7 
may suggest a role for the downstream residues in retrocyclin 
processing. These results indicated that biologically active 
recombinant retrocyclin peptides can be synthesized in 
human promyelocytic cells. 
The presence of the resulting expressed retrocyclin pep- 5 
tides in promyelocytic cells were confirmed using immun-
ostaining, particularly by the immunofluorescence staining of 
stably transfected HL60 cells. As shown in FIGS. 3A and 3B, 
for example, immuno-dotblot analyses revealed that an anti-
RC-101 antibody specifically recognized lysine-containing 10 
human retrocyclin analogs (synthetic RC-101 and RC-101_ 
2K) and RC-100 (i.e. wild type form) to a lesser extent (FIG. 
3A), but not human neutrophil peptides 1-3, or peptides with 
very similar tertiary structure including rhesus theta 
defensin-1 (RTD-1) and protegrin-1 (PG-1) (FIG. 3B). As 15 
shown in FIG. 3C, an anti-RC-101 antibody was used to 
visualize the expressed retrocyclin polypeptides in the stably 
transfected HL60 cells by immunofluorescence staining, 
which revealed that cells expressing R1R3 heterodimer ret-
rocyclin polypeptides and cells expressing A1A3 retrocyclin 20 
polypeptides were brightly stained as compared to Vector 
Control (VC) cells. Slides treated with pre-immune serum 
showed no staining (data not shown). The staining of cells 
producing A1A3 retrocyclin polypeptides was brighter than 
cells expressing R1R3 retrocyclin polypeptides and the mor- 25 
phology of A1A3 was smaller than VC cells. 
Thereafter, the presence of the expressed retrocyclin pep-
tides from the cell extracts was confirmed. In particular, 
reverse-phase high pressure liquid chromatography HPLC 
(RP-HPLC) was utilized to purify the recombinant retrocy- 30 
clin peptides from stably transfected HL60 cell extracts. FIG. 
4A shows the RP-HPLC trace oftheA1A3 heterodimer (RC-
101) and synthetic RC-101. Synthetic RC-101 was recovered 
8 
data not shown) and is in agreement with reduction of the 
three disulfide bridges in the molecule. Furthermore, treat-
ment with iodoacetamide yielded mass species of 2238.081 
Da for the A1A3 fraction 26 and 2238.071 Da for RC-101 
corresponding to the predicted 6-fold-alkylated form of 
RC-101 (expected mass=2238.097 Da). Comparison of spec-
trum of the Lys-C digest of reduced/alkylated synthetic 
RC-101_2K (peak at 1123.577 Da; peptide cleaved at two 
Lys-Gly bonds; See FIG. 4D), synthetic RC-101 (peak at 
2256.097 Da; peptide cleaved at a single Lys-Gly bond; 
N-terminal sequence determined as: Gly-Ile-Cys-Arg-; See 
FIG. 4E) andA1A3 fraction 26 (peak at 2256.010 Da) sug-
gests that the A1A3 cells are expressing RC-101 (See FIG. 
4F). These data confirmed that correctly folded mature retro-
cyclin polypeptides can be expressed by human cells. 
In accordance with another aspect of the present invention, 
the inventor has surprisingly found yet another process for 
expressing retrocyclin nonapeptides endogenously. In par-
ticular, the present inventor has found that the use of specific 
read-through mediating agents enable varying degrees ofter-
mination codon read-through to produce retrocyclin non-
apeptides. Thus, in one embodiment of the present invention, 
there is provided a method for inducing the expression of a 
retrocyclin polypeptide in a manimalian host cell having a 
naturally-occurring sequence encoding for the retrocyclin 
polypeptide, wherein the naturally-occurring sequence has a 
premature termination codon. The process comprises induc-
ing expression of the retrocyclin polypeptide in the mamma-
lian host cell via contacting the mammalian host cell with an 
amount of a read-through mediating agent effective to read-
through the premature termination codon and allow for 
expression of the retrocyclin nonapeptide. By "an amount of 
a read-through mediating agent effective to" as used herein, it 
is meant an amount effective, at dosages and for periods of in fractions collected at 26-28 min. A1A3 HPLC fractions 
collected from 23-30 minutes were analyzed on a 16% Tri-
cine-SDS-gel. Control samples did not contain any protein 
bands at the expected size while fractions from R1R3 cell 
extracts revealed protein bands of about 6 kDa size (not 
shown). A1A3 HPLC fractions revealed multiple protein 
bands, which were analyzed by western blot (FIG. 4B). The 
western blot analysis revealed bands at sizes corresponding to 
a monomer, dimer and trimer of retrocyclin. The presence of 
multimeric forms ofretrocyclin had previously been uncov-
ered by Daly and colleagues [29]. 
35 time necessary to achieve the desired result. 
Furthermore, the RP-HPLC purifiedA1A3 fractions inhib-
ited entry ofHIV-1 BaL in TZM-bl cells (FIG. 4C). The IC50 
of retrocyclin peptides expressed by A1A3 cells (2 µg/ml) 
was similar to that of synthetic RC-101 (1.25 µg/ml) [8]. It is 
specifically believed that retrocyclins inhibit the fusion of 
HIV-1 Env by selectively binding to the C-terminal heptad 
repeat region on gp41 blocking 6-helix bundle formation [ 15, 
16]. RC-101 is a congener ofretrocyclin with a single argin-
ine to lysine substitution that retains structural and functional 
similarity to retrocyclin [ 4]. RC-101 exhibited enhanced anti-
HIV-1 activity against over two dozen primary isolates from 
several clades [7, 8], and did not induce inflammation or 
toxicity in organotypic models of human cervicovaginal tis-
sue [17]. 
To determine the identity of the retrocyclin peptide 
expressed by A1A3-expressing cells (cells transfected with 
the Al and A3 sequence and expressing an A1A3 het-
erodimer), an HPLC fraction 26 (collected at 26 minutes) was 
analyzed by mass spectrometric analysis (MALDI-TOF-
MS). Analysis of the A1A3 fraction revealed peaks with 
masses 1889.775 Da (oxidized) and 1895.890 Da (reduced), 
which is nearly identical to the expected mass of synthetic 
cyclic RC-101 (1889.85 Da and 1895.96 Da respectively; 
In one embodiment, the read-through mediating agent 
comprises an aminoglycoside. Thus, the aminoglycoside may 
include but is not limited to one or more of amikacin, arbeka-
cin, gentamycin, kanamycin, neomycin, netilmicin, paromo-
40 mycin, rhodostreptomycin, streptomycin, tobramycin, and 
apramycin. In a particular embodiment, the aminoglycoside 
is one or more of gentamycin, amikacin, or tobramycin. In 
another embodiment, the read-through mediating agent is 
Ataluren (PTC124®) available from PTC Therapeutics, Inc., 
45 Plainfield, N.J. 
Turning again to the figures, the ability of three exemplary 
aminoglycosides (gentamicin, amikacin, and tobramycin) 
were tested to induce termination codon read-through ofret-
rocyclin cDNA. The native retrocyclin gene was fused with a 
50 luciferase reporter at the C-terminus to create 2 constructs: 
unrescued RC-101 and rescued RC-101 (positive control) as 
shown in FIG. SA. These constructs were transfected into 
HOS-CD4-CCR5 cells, grown in the presence of varying 
concentrations of aminoglycosides, and the degree of read-
55 through quantified by measuring luciferase. Application of 
tobramycin (10 µg/ml) was the most effective, producing a 
26-fold increase in read-through (P<0.0007; FIG. SB). 
Having thus established the optimal aminoglycoside con-
centration required to achieve read-through of retrocylin 
60 cDNA, it was next determined if aminoglycosides could 
restore the translation and anti-HIV-I activity of native retro-
cyclin peptides. HeLa-derived cells lines, such as TZM-bl 
cells can natively express retrocyclin mRNA (data not 
shown). Aminoglycosides were applied to TZM-bl cells and 
65 challenged them with HIV-1 BaL. It was found that cells 
treated with gentamicin and tobramycin significantly 
(P<0.0005 andP<0.0001 respectively) inhibited HIV-1 infec-
US 8,765,698 B2 
9 
tion as compared to untreated cells (FIG. SC). The effect was 
modest when compared to inhibition by synthetic peptides. 
Cell viability, determined by a tetrazolium based MTT assay, 
was not affected by the application of aminoglycosides at the 
mentioned concentrations (FIG. SE). 
In order to visualize the retrocyclins expressed by applica-
tion of aminoglycosides, immunostaining was performed. 
TZM-bl cells were treated with PBS control or 10 µg/ml 
to bramycin and stained with anti-retrocyclin antibody or pre-
immune serum. Control cells showed no staining while cells 
treated with tobramycin revealed brightly stained cells sug-
gesting that aminoglycosides can induce the expression of 
retrocyclin peptides (FIG. SD). 
TZM-bl cells were incubated with tobramycin (10 µg/ml) 
for 24 hr, and then treated the cells with preimmune or anti-
retrocyclin serum followed by infection with HIV-1. FIG. SF 
reveals that cells treated with preimmune serum showed a 
modest yet significant reduction in infection as compared to 
cells treated with anti-retrocyclin antibodies (P<0.018), sug-
gesting that the antibody inhibited the endogenous retrocy-
clins. These data confirm that the anti-HIV-1 activity 
observed is due to the endogenous retrocyclin peptides 
expressed when tobramycin was applied to cells. 
Referring to FIGS. 6A-6D, the ability of aminoglycosides 
to induce the expression of retrocyclin peptides in an organo-
typic model cervicovaginal tissue was analyzed. Tissues were 
treated apically with tobramycin or control (PBS) for 24 hr 
and anti-retrocyclin immunohistochemical analysis was per-
formed. Tissues treated with tobramycin alone and stained 
with anti-retrocyclin antibody revealed brightly stained cells 
(FIG. 6A) suggesting that production of retrocyclin peptides 
is induced upon application of aminoglycosides. Lactate 
Dehydrogenase (LDH) activity in the medium underlying the 
tissues was performed to determine tissue cytotoxicity. The 
LDH assay revealed that application of 10 µg/ml tobramycin 
was not cytotoxic to the tissues (FIG. 6B). In addition, treat-
ment of tobramycin did not affect the metabolic activity 
adversely, which was determined by an MTT assay per-
formed on one tissue (data not shown). 
In order to purify endogenous retrocyclins expressed in the 
tissues, reverse-phase HPLC was utilized. FIG. 6C shows an 
HPLC trace of control, tobramycin-treated tissue extracts as 
compared to synthetic RC-100 peptide. Synthetic RC-100 
peptide was recovered in fractions collected at 27-29 minutes. 
Corresponding fractions from control and tobramycin-
treated tissues were analyzed by immuno-dotblot analysis 
using the anti-RC-101 antibody. FIG. 6D shows that retrocy-
clin polypeptides were recovered in the 27-29 min fractions in 
tobramycin-treated tissue samples, but not in control tissue 
samples. The amount of retrocyclin polypeptides (e.g., 
RC-100) expressed in tobramycin-treated cervicovaginal tis-
sues was estimated by densitometry to be approximately 1.6 
µg/tissue. Together these studies show that aminoglycosides 
suppress the premature termination codon of retrocyclin tran-
scripts and restore the ability of cervicovaginal tissues to 
protect cells from HIV-1. 
Accordingly, in another aspect of the present invention, 
there is provided a process for inducing the expression of a 
retrocyclin polypeptide in a mammalian host cell. The host 
cell has a naturally-occurring sequence encoding for the ret-
rocyclin polypeptide, wherein the naturally-occurring 
sequence has a premature termination codon. The process 
comprises inducing expression of the retrocyclin polypeptide 
in the host cell via contacting the host cell with an amount of 
a read-through mediating agent effective to read-through the 
premature termination codon and allow for expression of the 
retrocyclin polypeptide. In one embodiment, the read-
10 
through mediating agent comprises an aminoglycoside. In a 
particular embodiment, the aminoglycoside is one or more of 
amikacin, arbekacin, gentamycin, kanamycin, neomycin, 
netilmicin, paromomycin, rhodostreptomycin, streptomycin, 
tobramycin, and apramycin. In one embodiment, the host cell 
is a mammalian ho st cell, e.g., a human host cell. The host cell 
may be a mucosa! cell, an ocular cell, an epithelial cell, a 
cervicovaginal cell, or promyelocytic cells, for example. 
In accordance with another aspect of the present invention, 
10 there is provided a process for inhibiting HIV-1 virus entry 
into a host cell of a mammalian subject comprising adminis-
tering to the mammalian subject an amount of a read-through 
mediating agent effective to induce expression of a retrocy-
clin polypeptide in the host cell. In one embodiment, the 
15 read-through mediating agent is an aminoglycoside that is 
formulated into a topical composition and administered topi-
cally. In another embodiment, the aminoglycoside is admin-
istered orally in a suitable formulation, optionally comprising 
pharmaceutical carriers and excipients as are known in the art. 
20 In a particular embodiment, the host cell is a female human 
cell and the read-through mediating agent is administered 
topically to a vaginal mucosa of the subject. In yet another 
embodiment, the host cell is a nasal cell or nasal mucosa! cell, 
and the read-through mediating agent is administered topi-
25 cally to the nasal mucosa of the subject. 
In accordance with another aspect of the present invention, 
there is provided a pharmaceutical composition for inhibiting 
HIV-1 cell entry comprising an amount of an aminoglycoside 
effective to induce expression of a retrocyclin polypeptide in 
30 a mammalian host cell. In one embodiment, the pharmaceu-
tical composition, or a product made therefrom, is formulated 
to be consumed orally. In another embodiment, the pharma-
ceutical composition, or a product made therefrom, is a phar-
maceutical, an OTC medicament, an ointment, liquid, cream 
35 or other material suitable for topical application. Alterna-
tively, the pharmaceutical composition may be formulated to 
be suitable for oral, rectal, optical, buccal (e.g., sublingual), 
parenteral (e.g., subcutaneous, intramuscular, intradermal 
and intravenous) and transdermal administration. In one 
40 exemplary embodiment, a product for topical application 
may comprise at least 0.01 %, and up to 5.0%, by weight of the 
aminoglycoside. Different aminoglycosides are readily com-
mercially available from suitable sources. 
In addition, a topical composition may include other cos-
45 metic and pharmaceutical actives and excipients as desired. 
Such suitable cosmetic and pharmaceutical agents include, 
but are not limited to, antifungals, vitamins, anti-inflamma-
tory agents, antimicrobials, analgesics, nitric oxide synthase 
inhibitors, insect repellents, self-tanning agents, surfactants, 
50 moisturizers, stabilizers, preservatives, antiseptics, thicken-
ers, lubricants, humectants, chelating agents, skin penetration 
enhancers, emollients, fragrances and colorants. 
Further, any embodiment of the pharmaceutical composi-
tion may include one or more pharmaceutically acceptable 
55 adjuvants, carriers and/or excipients. Pharmaceutically 
acceptable adjuvants, carriers and/or excipients are well 
known in the art, for example as described in the Handbook of 
Pharmaceutical Excipients, second edition, American Phar-
maceutical Association, 1994 (the entirety of which is incor-
60 porated by reference herein). 
A pharmaceutical composition suitable for oral adminis-
tration may be prepared in discrete units, such as capsules, 
cachets, lozenges, or tablets, each containing a predetermined 
amount of the extract; as a powder or granules; as a solution 
65 or a suspension in an aqueous or non-aqueous liquid; or as an 
oil-in-water or water-in-oil emulsion. Such compositions can 
be prepared by any suitable method of pharmacy, which 
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includes the step ofbringing into association the read-through 
mediating agent, e.g., an aminoglycoside, and one or more 
suitable carriers (which can contain one or more accessory 
ingredients as noted above). Generally, the compositions of 
the invention are prepared by uniformly and intimately 
admixing the aminoglycoside with a liquid or finely divided 
solid carrier, or both, and then, if necessary, shaping the 
resulting mixture. For example, a tablet can be prepared by 
comprising or molding a powder or granules containing the 
extract, optionally with one or more accessory ingredients. 
Compressed tablets can be prepared by compressing in a 
suitable machine, the extracts in the form of a powder or 
granules optionally mixed with a binder, lubricant, inert dilu-
ents, and/or surface active/dispersing agent(s). Molded tab-
lets can be made by molding, in a suitable machine, the 
powdered compound moistened with an inert liquid binder. 
marrow, thymus, testis and skeletal muscle [14] and cervico-
vaginal epithelia. By transfecting host cells, e.g., human 
myeloid cells, ocular cells, or mucosa! cells, with delivery 
vectors, e.g., plasmids, comprising containing retrocyclin 
constructs without a premature termination codon, it was 
demonstrated that the "machinery" needed to process, trim, 
splice and oxidize retrocyclin precursors was available in 
human cells, e.g., human myeloid or mucosa! cells. Two sets 
of expression constructs were transfected into cells: a shorter 
10 form (Rl R3) that terminates at the end of the retrocyclin gene 
and a longer form that contains (A1A3) additional 3' untrans-
lated residues (UTR). A1A3 cells expressed higher levels of 
retrocyclin peptides as compared to R1R3 cells indicating a 
15 role for additional residues in the translational efficiency of 
these peptides. While not wishing to be bound by theory, it is 
believed this may due to the fact that the length of the 3'-UTR 
regulates translation efficiency [28, 30]. Further, the present 
inventor has found that aminoglycoside-treated cells and cer-
Suitable fillers for orally administrable pharmaceutical 
compositions, such as sugars, e.g., lactose, saccharose, man-
nitol or sorbitol, cellulose preparations and/or calcium phos-
phates, e.g., tricalcium phosphate or calcium hydrogen phos-
phate, and also binders such as starch paste using, e.g., com, 
wheat, rice or potato starch, gelatin, tragacanth, methylcellu-
ose and/or polyvinylpyrrolidone, and, if desired, disintegra-
tors, such as the above-mentioned starches, also carboxym-
ethyl starch, cross linked polyvinyl pyrrolidone, agar or 
alginic acid or a salt thereof, such as sodium alginate. Excipi-
ents can be flow conditioners and lubricants, for example 
silicic acid, talc, stearic acid or salts thereof, such as magne-
sium or calcium stearate, and/or polyethylene glycol. Tablets, 
capsules, or Dragee cores can be provided with suitable, 30 
optionally enteric, coatings, there being used, inter alia, con-
centrated sugar solutions which can comprise gum arabic, 
talc, polyvinylpyrrolidone, polyethylene glycol and/or tita-
nium dioxide, or coating solutionsin suitable organic solvents 
20 vicovaginal tissues may express retrocyclin polypeptides by 
suppressing the premature termination codon in their endog-
enous mRNA transcript. 
In one embodiment, the methods, constructs, and pharma-
ceutical products described herein are effective for preventing 
25 and/or treating sexually transmitted infections (STI' s) includ-
ing, but not limited to, HIV-1, HIV-2, and other bacterial 
infections. For example, in one embodiment, the methods, 
constructs, and pharmaceutical products described herein 
may be useful in preventing nasal carriage of Staphylococcus 
aureus. 
Since approximately 30% of inherited disorders may result 
from premature termination codon mutations, there has been 
tremendous interest and some progress in developing and 
applying agents that can read-through premature UAA, UAG 
or VGA termination codons [25]. In a sense, human retrocy-
clin-deficiency is also an inherited disorder, albeit one with an 
incidence of 100%. It is caused by a premature termination 
codon mutation that occurred after human lineage diverged 
from the lineage we share with orangutans, lesser apes and 
or solvent mixtures, or, forthe preparation of enteric coatings, 35 
solutions of suitable cellulose preparations, such as acetyl-
cellulose phthalate or hydroxypropylmethylcellulose phtha-
late. Dyes or pigments can be added to the tablets or dragee 
coatings, for example for identification purposes or to indi-
cate different doses of active ingredients. 
Other orally administrable pharmaceutical compositions 
are dry-filled capsules made, for example, of gelatin, and soft, 
sealed capsules made of gelatin and a plasticizer, such as 
glycerol or sorbitol. The dry-filled capsules can comprise the 
extracts in the form of granules, for example in admixture 45 
with fillers, such as lactose, binders, such as starches, and/or 
glicants, such as talc or magnesium stearate, and, where 
appropriate, stabilizers. In soft capsules, the extract is pref-
erably dissolved or suspended in suitable liquids, such as fatty 
oils, paraffin oil or liquid polyethylene glycols, to which 50 
stabilizers can also be added. 
40 old world monkeys. Since HIV-1 and other viruses that cur-
rently infect humans have evolved in the absence of selective 
pressure exerted by retrocyclins, the ability to reawaken this 
ancestral molecule could be used to strengthen the innate 
In summary, identifying effective drugs to prevent sexually 
transmitted infections and other viral or bacterial infections is 
essential for countering the spread of these diseases. Exog-
enous (synthetic) retrocyclin polypeptides exhibit full activ-
ity in the complex environment of vaginal fluid and the pep-
tide is very well tolerated in organotypic human 
cervicovaginal tissue models [ 17]. Moreover, HIV-1 evolves 
little resistance during continued passaging in the presence of 
the peptide [18]. For these and other reasons, retrocyclins 
have emerged as potential topical microbicides to protect 
against sexually-transmitted HIV-1 infections. 
In the present invention, the present inventor has developed 
novel and nonobvious human pseudogenes that encode the 
demidefensin precursors whose post-translational processing 
gives rise to mature retrocyclin peptides are expressed at the 
mRNA level in multiple organs, including the spleen, bone 
immune system's ability to prevent or limit the infections 
they now induce. 
Example 1 
Maintenance of Cells, Tissues and Viruses 
HL60 cells [33, 34] obtained from ATCC were cultured in 
Iscoves's DMEM with 20% FBS, 100 U/ml penicillin and 
100 µg/ml streptomycin (120). TZM-bl cells [35] stably 
expressing CD4, CCR5 & CXCR4, has firefly luciferase gene 
55 under the control of HIV-1 promoter (from Dr. Kappes, Dr. 
Wu and Tranzyme Inc). TZM-bl, HOS-CD4-CCR5 [36, 37] 
(from Dr. Landau), PM! cells [38], (from Dr. Reitz) and 
HIV-1 BaL, an R5 tropic strain, were all procured through the 
NIH AIDS Research and Reference Reagent program. HIV-1 
60 BaL viral stocks were prepared by infecting PM! cells [18]. 
Peripheral blood mononuclear cells (PBMC) were isolated 
from blood drawn from a healthy HIV-1 seronegative donor 
as per the guidelines of the institutional review board of 
University of Central Florida. PBMCs were isolated using 
65 Lymphosep® (MP biomedicals LLC, Solon, Ohio), and cul-
tured in RPMI-1640 medium with 10% FBS (RIO) supple-
mented with 50 Units of IL-2 (R10-50U) and 5 µg/ml of 
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phytohemagglutinin (PHA) for 3 days. The cells were then 
resuspended in R10-50U at a density of0.8xl 06 cells/ml and 
grown for 5-6 days. 
Cervicovaginal tissues (EpiVaginal™) were obtained from 
MatTek Corp., Ashland, Mass. and maintained in proprietary 5 
growth medium as per the company's guidelines. The tissues 
were composed of a full-thickness, stratified vaginal-ectocer-
vical layer intermixed with Langehans cells and underlying 
lamina propria. The tissues were allowed to grow on transwell 
cell culture inserts at the air-liquid interface. 10 
Example 2 
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dried and resuspended in 100 µl of0.01 % acetic acid. 100 µg 
of synthetic RC-101 peptide was also affinity purified as 
positive control (RC-101 IP). 
Example 4 
Luciferase-Based Infection Assay to Determine 
Anti-HIV-1 Activity 
TZM-bl cells (4000 cells/well; 96-well plate) were 
infected with HIV-1 Ba L (2-6.5 ng/ml of p24ga~ in the 
presence of vehicle (0.01 % acetic acid) or HL60 extracts 
(from 0.25xl06 control or A1A3 or R1R3 cells) or affinity 
purified extracts (from 0.625xl06 control HL60 or VC or Creation of Retrocyclin Constructs and Stably 
Transfected HL60 Cells 15 R1R3 or AlA3 cells or RC-101 IP diluted 1:32 times) or 
RC-101 (20 µg/ml) (positive control) for 24 hr. Treatments 
were then removed and the infection was quantified by mea-
suring luciferase using Bright-Gia reagents (Promega, Madi-
son, Wis.) in an LMax luminometer (Molecular Devices, 
Retrocyclin cDNA was amplified from human bone mar-
row cDNA and cloned into pCRII-TOPO vector (Invitrogen, 
Carlsbad, Calif.). Cole et al, Proc Natl Acad Sci USA. 2002 
Feb. 19; 99(4): 1813-1818, provides information on the 
human retrocyclin gene and protein, which reveals the termi-
nation codon 017atthe17 codonposition(seeFIG.1). Two 
mutations, Termination codon C017)~Gln (Q.17) and Arg 
(R70)~Lys (K70) were introduced, either (2017Q alone 
(RC-100) or both (RC-101) using Quick Change® site-di- 25 
rected mutagenesis (Stratagene, LaJolla, Calif.) and sub-
cloned in-frame into the phCMV-luc-FSR vector (Genlantis, 
San Diego, Calif.) to generate four constructs Rl, R3, Al and 
A3 (FIG. lA). Plasmids Rl and Al encode RC-100 nonapep-
tide while R3 and A3 encode RC-101 nonapeptide. Con- 30 
structs Al andA3 have a longer insert that includes additional 
downstream residues. HL60 cells (107 cells/400 µl Iscove's 
DMEM) were co-transfected with 2 µg each oflinearized Rl, 
20 S=yvale, Calif.). Cytotoxicity and metabolic activity of 
cells were verified by a tetrazolium-based MTT assay (R& D 
systems, Minneapolis, Minn.) performed on identically 
treated cells. 
R3 or Al, A3 or phCMV-luc vector alone, by electroporation 
(exponential decay wave mode-280 V; 975 µF) and selected 35 
in I20 medium with 300 µg/ml G418 sulfate. Stable transfec-
tants thus produced were named according to the constructs 
used for co-transfection (R1R3, A1A3 or Vector Control: 
VC). Presence of these constructs in the cells was verified 
using PCR of genomic DNA (FIG. 7 A). PCR conditions used 40 
were the following: initial denaturation at 95° C. for 3 min; 30 
cycles of95° C. for 1 min, 58° C. for 1 min, 72° C. for 2 min 
followed by a final extension at 72° C. for 7 min. Sequences 
of the primers used for the PCR reaction are listed in Table 1. 
RNA was extracted from 106 cells (HL60, VC, R1R3 and 45 
AlA3)usingTRizol (Invitrogen), cleaned withDNaseI (Am-
bion Inc., Austin Tex.) and cDNA synthesized (iScript™, 
BioRad, Hercules Calif.). Expression of recombinant genes 
was verified by PCR from the cDNA and subsequent restric-
tion digestion using HpyCH4V (New England Biolabs, Bev- 50 
erly, Mass.) (FIGS. 7B and 7C). 
Example 3 
Acid Extraction and Affinity Purification of 
Retrocyclin Peptides 
HL60 cells (control, VC, R1R3 andA1A3) were extracted 
with 5% acetic acid by vortexing for 20 min, centrifuged for 
55 
10 min at 10,000xg, supernatants were then vacuum-dried 60 
and resuspended in 0.01 % acetic acid. HL60 acid extracts 
(equivalent of 20x 106 cells) were affinity purified using anti-
RC-101 polyclonal antisera immobilized to a Carbolink™ 
coupling gel (Pierce Biotechnology Inc. Rockford, Ill.) pre-
pared according to the manufacturer's instructions. Immu- 65 
nopurified samples were desalted using Sep-Pak C-18 car-
tridges (Waters Corp., Milford, Mass.). The elutes were then 
Example 5 
Antiviral Infection Assay in Suspension Cells and 
HIV-1 p24gag ELISA 
Acid extracts of stably transfected HL60 cells were 
vacuum-driedandresuspendedinPBS. PM! cells (105 cells) 
or PBMCs (106 cells) were treated with PBS (vehicle) or 
HL60extracts (from 104 cells for PM! and 105 for PBMCs) of 
control cells or A1A3 cells or 10 µg/ml of synthetic RC-101 
and infected with HIV-1 BaL (2 ng of p24/ml) in 100 µl of 
RPMI medium with 20% FBS (R20) for 2 hr. Cells were then 
washed with 2 ml of R20, resuspended in fresh medium 
containing the treatments and cultured for 5-9 days. Subse-
quently, on alternate days culture supernatants were collected 
and fresh medium with the corresponding treatments was 
added. Viability of the cells was measured using trypan blue 
exclusion assay. Amount of HIV-1 virus in the culture super-
natants was quantified by ELISA for HIV-1 p24gag (Perkin 
Elmer, Waltham, Mass.). 
Peptides RC-100, RC-lOOb, RC-101, RC-101_2K, syn-
thetic protegrin-1 (PG-1), Rhesus theta defensin-1 (RTD-1) 
and human neutrophil peptides 1-3 (HNP 1-3) or unknown 
samples were dotted ( 4 µl dot) as indicated on a 0.22 µm 
PVDF membrane (Immobilon-P) that was activated with 
methanol and presoaked in TBS. The membrane was then 
probed with 1:1000 rabbit anti-RC-101 antibody and devel-
oped using Immun™-star HRP reagent (BioRad) [17]. 
Example 6 
Immunostaining of Stably Transfected HL60 Cells 
UsingAnti-RC-101 Antibody 
HL60 cells (VC, R1R3 and A1A3) were fixed on slides 
(100,000 cells/slide), immersed in 10% Formalin in PBS for 
10 min, washed (PBS for 2 min), incubated in Target retrieval 
solution (Dako NorthAmerica Inc., Carpinteria, Calif.) for 20 
min at 95° C., cooled to 25° C., washed, blocked (2% Goat 
Serum, 0.1%Triton-X,0.05% Tween-20, antibody buffer (10 
mg/ml BSA/1 mg/ml gelatin/PBS) for 20 min and incubated 
in rabbit pre-immune serum or rabbit anti-RC-101 antibody 
(1:5000 in antibody buffer) overnight. Slides were washed, 
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incubated in biotinylated goat anti-rabbit IgG antibody (1 :20, 
000 in 1 % goat serum/PBS for 30 min), followed by addi-
tional washing and treatment with Fluorescein-Avidin D 
(Vector Laboratories Inc.; 1 :500 in PBS for 30 min). Cover 
slips were mounted using Vectashield fluorescence mounting 5 
medium and visualized using a Zeiss Axiovert 200M micro-
scope system. 
Tissues for immunofluorescence staining were fixed in 4% 
paraformaldehyde and slides were prepared by Mass Histol-
ogy (Worcester, Mass.). The slides were deparaffinized, 10 
washed with TBS, and stained with anti-retrocyclin or pre-
immune serum and immunostained the same way as cells. 
The slides were then visualized on a Zeiss Axiovert 200M 
microscope system with 450 ms exposure time for all slides. 
16 
ZipTip (Millipore Corp., Billerica, Mass.) and subjected to 
Edman degradation on cLC-Procise sequencer (Applied Bio-
systems, Forest City, Calif.). 
Example 8 
Aminoglycoside Mediated Read-Through of 
Termination Codon 
Wildtype and mutant retrocyclin cDNAs were subcloned 
into phCMV-luc-FSR vector to create unrescued RC-101 and 
rescued RC-101 C-terminal luciferase fusion constructs, and 
verified by sequencing. HOS-CD4-CCR5 cells were cultured 
in antibiotic free growth medium (DlO-) and co-transfected 
Example 6 
Separation of Proteins from Stably Transfected 
HL60 Extracts Using Reverse-Phase HPLC 
15 with 0.5 µg ofunrescued or rescued (positive control) RC-101 
plasmids along with 0.1 µg of phRL-CMV vector (transfec-
tion control containing renilla luciferase gene) using Effect-
ene transfection reagent (Qiagen, Valencia, Calif.). The next 
day cells were treated for 24 hr with the appropriate ami-
20 noglycoside ( 40 µg/ml amikacin or 5 µg/ml gentamicin or 10 
µg/ml tobramycin) or DlO- for control cells. Read-through 
was determined by measuring luciferase and renilla levels 
using a dual luciferase assay (Promega Corp., Madison, 
Acid extracts from control HL60 and A1A3 cells ( equiva-
lent oflOOxl 06 cells) were separated by RP-HPLC using the 
Alliance HT Waters 2795 Separations Module on a C18 Col-
umn equilibrated in solvent A (aqueous 0.1 % TFA). Elution 
was done with a gradient of0-95% solvent B (0.08% TFA in 25 
acetonitrile), for 75 min, at 1 ml/min. Collected fractions (1 
Wis.). 
TZM-bl cells ( 4000 cells/well; 96 well plate) were cultured 
in DlO- and treated with vehicle (PBS buffered DlO-) or 
peptides RC-101 or RC-100 (2.5 µg/ml each) as positive 
control or aminoglycosides as before for 30 min followed by 
infection with HIV-1 BaL (p24 of 2 ng/ml) at 37° C. for 24 hr. 
30 Subsequently, viral infection was quantified by measuring 
luciferase levels using Bright-Gia reagents (Promega). Cel-
lular metabolism was monitored by measuring reduction the 
ability of cellular dehydrogenases to reduce MTT to forma-
ml each) were vacuum dried and reconstituted in 100 µl of 
0.01 % acetic acid. Synthetic RC-101 peptide (control) was 
recovered from the fractions eluting at 26-28 min. A1A3 
HPLC fractions (#23-28) were electrophoresed on a 16% 
Tricine-SDS gel and electro blotted on a 0.22 µm PVDF mem-
brane at 180 mA for 22 min. The western blot membrane was 
then processed as described [17] and developed with Chemi-
Glow reagent (Alpha Innotech, San Leandro, Calif.). AlA3 
RP-HPLC fractions (27-30 min) were pooled and the concen- 35 
tration was determined to be (2.13 ng/µl) by densitometry 
measurements using Quantity one 1-D analysis (BioRad). A 
luciferase-based assay was used to verify the activity ofA1A3 
HPLC fractions (diluted 3 times in DlO) against HIV-1 BaL 
(2 ng p24/ml). 40 
MatTek cervicovaginal tissues treated with PBS (control) 
zan (R& D Systems). 
TZM-bl cells were cultured on coverslips and treated with 
PBS control or 10 µg/ml oftobramycin for 24 hr. The cover-
slips were then processed for immunofluorescence staining 
with anti-retrocyclin (rabbit anti-RC-101 antibody) or pre-
immune serum as described above. 
For antibody-mediated neutralization experiments, TZM-
bl cells ( 4000 cells/well; 96 well plate) were cultured in Dlo-
medium and treated with vehicle (PBS) or 10 µg/ml oftobra-
mycin for 24 hr. The next day, cells were treated with either 
rabbit preimmune or anti-retrocyclin serum diluted 1:10 in 
or 10 µg/ml tobramycin were extracted with T-PER® reagent 
(Pierce Biotechnology Inc. Rockford, Ill.) and separated by 
RP-HPLC. 20 µg of synthetic retrocyclin (RC-100) was also 
separated as a positive control. Synthetic RC-100 was eluted 45 DlO- medium containing tobramycin or RC-100 (2.5 µg/ml). 
in fractions collected at 27-29 min. Tissue samples eluted at 
27-29 min were vacuum-dried to near dryness and resus-
pendedin 100 µl of0.01 % acetic acid. HPLC fractions (27-29 
min) of MatTek tissue extracts (control or tobramycin-
treated) and synthetic RC-100 were analysed by immuno- 50 
dotblot analysis. 
Example 7 
Mass Spectrometric Analysis 55 
Two hours later the cells were infected with HIV-1 BaL (p24 
of 5 ng/ml) at 37° C. for 24 hr. Viral infection was quantified 
as described above. An MTT assay was performed to confirm 
that the treatments were not cytotoxic (data not shown). 
Example 9 
Application of Aminoglycosides to Organotypic 
Cervicovaginal Tissue Model 
Cervicovaginal tissues were treated topically with 100 µl of 
PBS (control; n=4) or with 10 µg/ml oftobramycin (n=8) for 
24 hr. Viability was assessed on control and tobramycin-
treated tissue (n=l) using MTT assay kit (MatTek Corp., 
60 Ashland, Mass.). Cytotoxicity was measured by quantifying 
lactate dehydrogenase (LDH) activity in the underlying 
medium collected 24 hr after treatment with PBS or tobramy-
cin by using CytoTox96 non-radioactive cytotoxicity assay 
A1A3 HPLC Fraction 26, RC-101 and RC-101_2K were 
reduced, alkylated and treated with Lys-C protease for 30 min 
before analyzing by mass spectrometry. In brief, 20 mM Tris 
[2-carboxyethyl]phosphine (TCEP) was used to reduce (30 
min at 25° C.) the samples, alkylated by incubating the 
samples with iodoacetamide (60 mM; 45 min at 25° C.; pH 
8-9) followed by digestion with Lys-C (Waka Chemicals, 
Richmond, Va.; 30 min at 37° C.) and subjected to MALDI-
TOF-MS analysis using a model 4700 Proteomics Analyzer 65 
(Applied Biosystems, Foster City, Calif.) as described previ-
ously [39]. Lys-C digested RC-101 was desalted using C18 
kit (Promega Corp., Madison, Wis.). 
Various modifications and variations of the described 
methods and system of the invention will be apparent to those 
skilled in the art without departing from the scope and spirit of 
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the invention. Although the invention has been described in 
connection with specific preferred embodiments, it should be 
understood that the invention as claimed should not be unduly 
limited to such specific embodiments. Indeed, various modi-
fications of the described modes for carrying out the invention 5 
which are obvious to those skilled in molecular biology or 
related fields are intended to be within the scope of the claims. 
The teachings of all cited references are incorporated herein 
in their entirety to the extent not inconsistent with the teach-
ings herein. 10 
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SEQ. ID. NO, 8,Arg Cys Ile 
SEQ. ID. NO, 9,Arg Cys Ile 
SEQ. ID. NO, 1,CGT TGT ATT 
SEQ. ID. NO, 2,CGC TGC ATC 
SEQ. ID. NO, 3,cGT TGT ATT 
SEQ. ID. NO, 4,cGC TGC ATC 
SEQ. ID. NO, 5 DNA 
1 ggagacccgg 
61 tctgtcaccc 
121 ctgtaggctc 
181 cctggagcag 
241 ccgctttcag 
301 ttataacgtc 
361 tgagcttgca 
421 ttgttactcc 
481 caagatttct 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 10 
<210> SEQ ID NO 1 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Retrocyclin 
<400> SEQUENCE, 1 
cgttgtattt gtggtcgtgg tatttgt 
<210> SEQ ID NO 2 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Retrocylin 
20 
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SEQUENCE LISTING 
Cys Gly Arg Gly Ile Cys 
Cys Gly Lys Gly Ile Cys 
TGT GGT CGT GGT ATT TGT 
TGC GGC CGC GGC ATC TGC 
TGT GGT AAA GGT ATT TGT 
TGC GGC AAG GGC ATC TGC 
gacagaggac tgctgtctgc cctccctctt cactctgcct accttgagga 
cagccatgag gaccttcgcc ctcctcactg ccatgcttct cctggtggcc 
aggcggagcc acttcaggca agagctgatg aagctgcagc ccaggagcag 
atgatcagga aatggctcat gcctttacat ggcatgaaag tgccgctctt 
actcagcgag aggcttgagg tgcatttgcg gaagaggaat ttgccgtttg 
gctttgggtc ctgcgccttt cgtggtacac tccaccggat ctgctgccgc 
gaatcaagaa acataagctc agaatttact ttgagagtta aaagaaattc 
tgtaccttgt cctccatttc cttttctcat ccaaaataaa taccttgttg 
ctcttt 
TABLE 1 
35 
Primers used for verification 
of retrocyclin constructs. 
Primer 
Name Sequence 
Accession Primer 
Number Location Template 
DEFT Fwd TCCTCACTGC AF526271.1 29-47 Genomic 
CATGCTTCT DNA 
40 AF355799 92-110 cDNA 
DEFT Rev TTATAACAAAC AF526271.1 897-918 Genomic 
GGCAAATTCCT DNA 
AF355799 285-306 cDNA 
27 
21 
<400> SEQUENCE, 2 
cgctgcatct gcggccgcgg catctgc 
<210> SEQ ID NO 3 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Retrocylin 
<400> SEQUENCE, 3 
cgttgtattt gtggtaaagg tatttgt 
<210> SEQ ID NO 4 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Retrocylins 
<400> SEQUENCE, 4 
cgctgcatct gcggcaaggg catctgc 
<210> SEQ ID NO 5 
<211> LENGTH, 496 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Retrocylin 
<400> SEQUENCE, 5 
ggagacccgg gacagaggac 
tctgtcaccc cagccatgag 
ctgtaggctc aggcggagcc 
cctggagcag atgatcagga 
ccgctttcag actcagcgag 
ttataacgtc gctttgggtc 
tgagcttgca gaatcaagaa 
ttgttactcc tgtaccttgt 
caagatttct ctcttt 
<210> SEQ ID NO 6 
<211> LENGTH, 19 
<212> TYPE, DNA 
tgctgtctgc 
gaccttcgcc 
acttcaggca 
aatggctcat 
aggcttgagg 
ctgcgccttt 
acataagctc 
cctccatttc 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 
tcctcactgc catgcttct 
<210> SEQ ID NO 7 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 7 
ttataacaaa cggcaaattc ct 
<210> SEQ ID NO 8 
<211> LENGTH, 27 
cctccctctt 
ctcctcactg 
agagctgatg 
gcctttacat 
tgcatttgcg 
cgtggtacac 
agaatttact 
cttttctcat 
US 8,765,698 B2 
22 
-continued 
27 
27 
27 
cactctgcct accttgagga 60 
ccatgcttct cctggtggcc 120 
aagctgcagc ccaggagcag 180 
ggcatgaaag tgccgctctt 240 
gaagaggaat ttgccgtttg 300 
tccaccggat ctgctgccgc 360 
ttgagagtta aaagaaattc 420 
ccaaaataaa taccttgttg 480 
496 
19 
22 
US 8,765,698 B2 
23 24 
-continued 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Retrocylin 
<400> SEQUENCE, 8 
Ala Arg Gly Cys Tyr Ser Ile Leu Glu Cys Tyr Ser Gly Leu Tyr Ala 
1 5 10 15 
Arg Gly Gly Leu Tyr Ile Leu Glu Cys Tyr Ser 
20 25 
<210> SEQ ID NO 9 
<211> LENGTH, 27 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Retrocylin 
<400> SEQUENCE, 9 
Ala Arg Gly Cys Tyr Ser Ile Leu Glu Cys Tyr Ser Gly Leu Tyr Leu 
1 5 10 15 
Tyr Ser Gly Leu Tyr Ile Leu Glu Cys Tyr Ser 
20 25 
<210> SEQ ID NO 10 
<211> LENGTH, 9 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 10 
Arg Cys Ile Cys Gly Arg Gly Ile Cys 
1 5 
The invention claimed is: wherein the read-through mediating agent comprises at 
least one of gentamicin and tobramycin. 1. A method for inducing the expression of a retrocyclin 
polypeptide to reduce infection in a mammalian vaginal 
mucosa! cell having a naturally-occurring sequence encoding 
for the retrocyclin polypeptide, the naturally-occurring 
sequence having a premature termination codon, the method 
2. A method for reducing infectious agent entry into a 
vaginal mucosa of a mammalian subject having a naturally-
40 occurring sequence encoding for a retrocyclin polypeptide, 
the naturally-occurring sequence having a premature termi-
nation codon, the method comprising: 
comprising: 
inducing expression of the retrocyclin polypeptide in the 
45 
mammalian vaginal mucosa! cell to reduce infectious 
agent entry into the mucosa! cell by contacting the vagi-
nal mucosa! cell with an amount ofa read-through medi-
ating agent effective to read-through the premature ter-
mination codon and allow for expression of the 
retrocyclin polypeptide; 
administering to the vaginal mucosa of the manimalian 
subject an amount of a read-through mediating agent 
effective to read-through the premature termination 
codon to induce expression of the retrocyclin polypep-
tide that reduces infectious agent entry into the vaginal 
mucosa, wherein the read-through mediating agent 
comprises at least one of gentamicin and tobramycin. 
* * * * * 
